Document Classification

Section Type: RESULTS

Text: VAT [-16 9 vs. 19 9 cm (2), tesamorelin vs. placebo ; treatment effect (95 % confidence interval) : -35 (-58, -12) cm (2) ; P = 0. 003], cIMT (-0. 03 0. 01 vs. 0. 01 0. 01 mm ; -0. 04 (-0. 07, -0. 01) mm ; P = 0. 02), log C-reactive protein (-0. 17 0. 04 vs. -0. 03 0. 05 mg/liter ; -0. 15 (-0. 30, -0. 01) mg/liter, P = 0. 04), and triglycerides (-26 16 vs. 12 8 mg/dl ; -37 (-67, -7) mg/dl ; P = 0. 02) improved significantly in the tesamorelin group vs. placebo.